TrialNeurourology and urodynamics2021

Cardiovascular safety of vibegron, a new β3-adrenoceptor agonist, in older patients with overactive bladder: Post-hoc analysis of a randomized, placebo-controlled, double-blind comparative phase 3 study.

Masaki Yoshida et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.